Kevin M. Slawin, Chief Technology Officer at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 24,000 shares at $20.65 ($496K) on 2015-11-16, disclosed to the SEC on 2015-11-18.
Scheduled sale ($496k) by Chief Technology Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.65 | 4,000 | $83K | 16.7% |
| 2 | $20.65 | 6,000 | $124K | 25.0% |
| 3 | $20.65 | 14,000 | $289K | 58.3% |
| Total | $20.65 avg | 24,000 | $496K | 100% |
| Filing → |
| BLCM | SELL | 2016-09-23 | $936K | — | Filing → |
| BLCM | SELL | 2016-09-20 | $92K | — | Filing → |
| BLCM | SELL | 2016-08-17 | $2.0M | — | Filing → |